Glaukos Corp. ((GKOS)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Glaukos Corp. is conducting a study titled ‘A Randomized, Multicenter, Double-Masked, Vehicle-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With Persistent Corneal Epithelial Defects (NEXPEDE-1)’. The study aims to assess the safety and effectiveness of NEXAGON® in treating persistent corneal epithelial defects (PCED), a condition that can lead to significant vision problems.
The intervention being tested is NEXAGON®, a lufepirsen ophthalmic gel, which is an unmodified connexin43 antisense oligonucleotide. It is applied topically to the eye in both high and low dose concentrations, with a placebo comparator also being used.
This interventional study is randomized with a parallel assignment model. It employs quadruple masking, meaning that the participant, care provider, investigator, and outcomes assessor are all blinded to the treatment allocation. The primary purpose of the study is treatment-focused.
The study began on June 20, 2023, and is currently recruiting participants. The last update was submitted on July 21, 2025. These dates are crucial for tracking the study’s progress and anticipated completion.
The outcome of this study could significantly impact Glaukos Corp.’s stock performance, as successful results may enhance investor confidence and market position. It is essential to monitor how this development compares with competitors in the ophthalmic treatment industry.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.